Geben Sie eine Aktie oder eine Kryptowährung in der Suchleiste an, um eine Zusammenfassung zu erhalten
Marksans Pharma Limited
MARKSANSMarksans Pharma Limited, together with its subsidiaries, engages in the research, manufacturing, marketing, and sale of pharmaceutical formulations in the United States, North America, Europe, the United Kingdom, Australia, New Zealand, and internationally. The company offers products in the pain management, upper respiratory, cardiovascular, central nervous system, anti-diabetic, gastrointestinal, analgesics, upper respiratory, ear care, skincare, anticancer, anti-ulcerative, anti-allergy, antiviral, dietary, cardiac, dermatology, antihistamines, anti-fungal, anti-viral, laxatives, and cold and cough therapeutic areas. It also produces a range of solid oral dosage forms, including tablets and hard gelatin capsules; soft gels; essential oils; ointments; and creams and liquids, as well as prescription drugs. The company provides its products to supermarkets, high street retailers, pharmacy chains, and wholesalers. Marksans Pharma Limited was incorporated in 1992 and is headquartered in Mumbai, India. Address: Grandeur, Mumbai, India, 400053
Analytics
Zielpreis von Wall Street
2 617.34 INRKGV
40.8144Dividendenrendite
0.2 %Laufendes Jahr
Letztes Jahr
Laufendes Quartal
Letztes Quartal
Laufendes Jahr
Letztes Jahr
Laufendes Quartal
Letztes Quartal
Schlüsselzahlen MARKSANS
Dividenden-Analyse MARKSANS
Dividendenwachstum über 5 Jahre
900 %Kontinuierliches Wachstum
1 JahrAusschüttungsquote 5-Jahres-Durchschnitt
5 %Verlauf der Dividende MARKSANS
Bewertung der Aktie MARKSANS
Finanzen MARKSANS
Ergebnisse | 2019 | Dynamik |